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Systemic lupus erythematosus (SLE) is a complex disease, 
including serological diﬀ  erences between patients from 
diﬀ  erent ethnicities [1]. Clinically, the range of illness is 
great - patients may have life-threatening manifestations, 
or the disease may not be much more than a nuisance. 
An SLE patient of ours once noted she was sitting next to 
someone else with SLE in the waiting area, but that they 
seemed to have nothing in common but the diagnosis. 
Th  e patient was, understandably, suspicious that two 
people could share the diagnosis but otherwise not have 
any shared feature. Th  at one must meet only 4 of 11 
criteria to be classiﬁ  ed as SLE demonstrates that this is 
indeed the case [2].
Historically, and perhaps still, the major evidence that 
SLE is autoimmune is the presence of antibodies in the 
serum of SLE patients that bind self-structures. Here, 
too, the disease is extremely complex. Antinuclear 
antibody is a near-universal ﬁ  nding. Antibodies binding 
double-stranded DNA (dsDNA) are not nearly as 
common but are speciﬁ  c for the disease, and are strongly 
associated with kidney disease [3]. Antibodies to extrac-
table nuclear antigens (anti-ENA) include anti-nRNP, 
anti-Sm, anti-Ro (or SSA) and anti-La (or SSB). Numer-
ous other antibodies are found in the sera of patients with 
SLE, almost too numerous to keep up with.
What, then, might be useful properties of auto  anti-
bodies in SLE? First, we should not forget that these 
antibodies have been useful in biology unrelated to 
clinical SLE. Anti-nRNP and anti-Sm played a critical 
part in deﬁ  ning the cellular role of the spliceosome [4]. In 
fact, without these naturally occurring antibodies to the 
spliceosome ribo  nucleoprotein components, we might 
still be working on how mature mRNA is produced.
How are autoantibodies of use in regards to SLE itself 
[5]? One area is diagnosis. Clearly this is the case for 
some speciﬁ  cities. If a patient is not antinuclear antibody 
positive, then she (occasionally he) has almost no chance 
of having SLE. On the other hand, some autoantibodies 
are highly speciﬁ  c for SLE, but not very sensitive. Anti-
dsDNA, anti-P and anti-Sm fall into this category in that 
they are exclusively, or virtually exclusively, found in the 
sera of persons with SLE, but only among a fraction of 
these patients (reviewed in [5]). Antibodies might give 
information about clinical manifestations or prognosis. 
Anti-dsDNA is associated with kidney disease [3]. In 
addition, a rising titer of anti-dsDNA can, when part-
nered with complement measurements, predict exacer-
ba  tions of the disease [6]. Th  e combination of anti-Ro 
and anti-La is associated with protection from kidney 
disease [7]. SLE autoantibodies also may inform us as to, 
and be involved in, pathogenesis of the illness. Such 
information might range from molecular mimicry [8] to 
toll-like receptor binding [9] to autoantibody immune 
complexes stimulating interferon, a key cytokine in the 
pathogenesis of SLE [10]. Th  us, autoantibodies are 
especially useful if they are helpful in eliminating or 
establishing the diagnosis, parsing patients in terms of 
prognosis or risk, or elucidating the underlying mecha-
nisms of the disease.
In a recent issue of Arthritis Research and Th  erapy, 
Monica Vázquez-Del Mercado and her colleagues extend 
their studies of a new autoantigen-autoantibody system, 
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© 2010 BioMed Central Ltdnamely, antibodies binding RNA helicase A (anti-RHA) 
[1]. Th   ese antibodies were found in the sera of 14 (23%) 
of 62 Mexican SLE patients using immunoprecipitation 
of  35S-methionine-labeled cells. Of particular interest, 
this is much higher than reported previously by this same 
group, using the same technique, among American SLE 
patients, where only 6% had the anti-RHA [11]. Other 
anti-ENA and anti-dsDNA antibodies had about the 
same frequency in this Mexican cohort as the previously 
studied white American group. Another diﬀ  erence was 
the tendency of anti-RHA to be stable in the Mexican 
SLE patients, but to disappear with time in the white 
Americans. Th  ere were not any important relationships 
between anti-RHA and disease activity or manifestations, 
including other autoantibodies.
Th   us, this new antibody is of interest because, at least 
so far, it is found only among patients with SLE. But there 
are caveats. First, perhaps anti-RHA will be found in 
patients with other illnesses once testing has taken place 
in large numbers. Th  ere is certainly precedent for this 
[12]. Second, the investigators used immunoprecipitation 
techniques that are not easily applied to clinical care. For 
several serologies, including anti-Sm and anti-dsDNA, 
development of high-throughput ELISA has led to a loss 
of disease speciﬁ  city. Th   at is, ELISA-based determination 
of anti-Sm or anti-dsDNA gives positive results in 
patients without SLE; therefore, one of the most impor-
tant clinical implications of these antibodies is lost.
Anti-RHA is also remarkable because the results of the 
present work [1] show an ethnic diﬀ  erence. SLE exhibits 
clinical, epidemiological and genetic diﬀ  erences in patients 
from disparate ethnicities; however, the etiology of these 
diﬀ  erences is unknown. If study of anti-RHA can give 
insights into the origin of such diﬀ   erences, be they 
genetic or environmental, then these antibodies will be 
important indeed.
So, do we need more autoantibodies in lupus? Th  e 
answer is a resounding yes, especially if a new auto-
antibody-autoantigen system can provide diagnostic or 
prognostic information, or help us understand the 
etiology and pathogenesis of the disease in general, or in 
a particular ethnic or racial group. Th  us far, anti-RHA 
meets these standards.
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